![Enrique Poradosu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Enrique Poradosu
Founder at NUVECTIS PHARMA, INC.
Net worth: 10 M $ as of 31/05/2024
Enrique Poradosu active positions
Companies | Position | Start | End |
---|---|---|---|
NUVECTIS PHARMA, INC. | Chief Tech/Sci/R&D Officer | 27/07/2020 | - |
Founder | 27/07/2020 | - |
Career history of Enrique Poradosu
Former positions of Enrique Poradosu
Companies | Position | Start | End |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2016 | 01/12/2020 |
KERYX BIOPHARMACEUTICALS | Chief Tech/Sci/R&D Officer | 01/01/2003 | 01/01/2016 |
Training of Enrique Poradosu
The Hebrew University of Jerusalem | Doctorate Degree |
Statistics
International
United States | 4 |
Israel | 2 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
NUVECTIS PHARMA, INC. | Health Technology |
Private companies | 2 |
---|---|
Keryx Biopharmaceuticals, Inc.
![]() Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
![]() Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Enrique Poradosu
- Experience